DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0045483 A1 STAHLY Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0045483 A1 STAHLY Et Al US 20160045483A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0045483 A1 STAHLY et al. (43) Pub. Date: Feb. 18, 2016 (54) SOLID FORMS COMPRISING Related U.S. Application Data 3-(4-AMINO-1-OXO-1,3-DIHYDRO ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE (60) Eyal application No. 61/805.425, filed on Mar. AND ACOFORMER, COMPOSITIONS AND s METHODS OF USE THEREOF (71) Applicant: CELGENE CORPORATION, Summit, Publication Classification NJ (US) (51) Int. Cl. (72) Inventors: G. Patrick STAHLY, West Lafayette, IN A613 L/454 (2006.01) (US); David JONAITIS, Brookston, IN A 6LX3/573 (2006.01) (US); Ho-Wah HUI, Basking Ridge, NJ (52) U.S. Cl. (US); Kevin J. KLOPFER, Flemington, CPC ............. A6 IK3I/454 (2013.01); A61 K3I/573 NJ (US) (2013.01) (73) Assignee: CELGENE CORPORATION, Summit, NJ (US) (57) ABSTRACT (21) Appl. No.: 14/780,495 Provided herein are solid forms comprising (a) 3-(4-amino (22) PCT Filed: Mar. 25, 2014 1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (Le nalidomide) and (b) a coformer. Pharmaceutical composi (86). PCT No.: PCT/US2O14/O31689 tions comprising the Solid forms and methods for treating, S371 (c)(1), preventing and managing various disorders are also dis (2) Date: Sep. 25, 2015 closed. Patent Application Publication Feb. 18, 2016 Sheet 1 of 35 US 2016/0045483 A1 5e004 4e--004 1. O S 3e--004 2e--004 1e--004 Oe--000 10 20 30 40 2-Theta (deg) FIG. 1 Patent Application Publication Feb. 18, 2016 Sheet 2 of 35 US 2016/0045483 A1 1.5e004 1.0e--004 s 5.0e--004 0.0e--000 10 20 50 to 2-Theta (deg) FIG. 2 Patent Application Publication Feb. 18, 2016 Sheet 3 of 35 US 2016/0045483 A1 5.0e--004 14.0e--004 O s ae 2 3.0e--004 2.0e--004 1.0e--004 0,0e--000 10 20 30 40 2-Theta (deg) FIG. 3 Patent Application Publication Feb. 18, 2016 Sheet 4 of 35 US 2016/0045483 A1 6.0e--004 5.0e--004 3. SS 4.0e+004 2Y 23.0e--004 9 2.0e--004 1,0e--004 0.0e--000 10 20 30 40 2-Theta (deg) FIG. 4 Patent Application Publication Feb. 18, 2016 Sheet 5 of 35 US 2016/0045483 A1 1S 2.0e--005 C i 10e--005 0.0e--000 10 20 30 40 2-Theta (deg) FIG. 5 Patent Application Publication Feb. 18, 2016 Sheet 6 of 35 US 2016/0045483 A1 2,0e--005 1 5 e - O O 5 'r 1,0e--005 5,0e--004 2-Theta (deg) FIG. 6 Patent Application Publication Feb. 18, 2016 Sheet 7 of 35 US 2016/0045483 A1 S000 lenalidomide/magnesium bromide cocrystal 2500 2000 1500 1000- w ? . Wyf 500- w Wy Now. 5 10 15 20 25 SO 35 40 Degrees Two Theta FIG. 7B Patent Application Publication Feb. 18, 2016 Sheet 8 of 35 US 2016/0045483 A1 DSC2.0075 110 TC2.0130 15.52%. 70-20O'C (1.056mg) se 60N 122,840 lenalidomide/magnesium bromide cocrystal 209.71C O O 50 100 150 200 250 300 350 ExO Up Temperature (C) FIG. 8 Patent Application Publication Feb. 18, 2016 Sheet 9 of 35 US 2016/0045483 A1 lenalidomide/magnesium bromide cocrystal 4.O 5 O 2 O O O 20 40 60 80 100 Percent Relative Humidity FIG. 9 Patent Application Publication Feb. 18, 2016 Sheet 10 of 35 US 2016/0045483 A1 lenalidomide/magnesium bromide COCrystal E | 3500 3000 2500 2000 1500 1000 500 Raman shift (cm-1) FIG. 10 Patent Application Publication Feb. 18, 2016 Sheet 11 of 35 US 2016/0045483 A1 N W lenolidomidel/magnesium bromide cocrystal 11 10 FIG. 11 Patent Application Publication Feb. 18, 2016 Sheet 12 of 35 US 2016/0045483 A1 FIG. 12 Patent Application Publication Feb. 18, 2016 Sheet 13 of 35 US 2016/0045483 A1 1.0e--005 E. e 5.0e+004 Oe--000 e O 20 30 40 2-Theta (deg) FIG. 13A 4. 3.53 10?O lenalidomide/malonic acid cocrystal 5 O 15 20 25 50 35 40 Degrees Two Theta FIG. 13B Patent Application Publication Feb. 18, 2016 Sheet 14 of 35 US 2016/0045483 A1 DSC20074 43.13%. 100-180C TG20129 (1.717mg) 159.44C 102.11C 110.75°C lenalidomide/malonic acid cocrystal "() 50 100 150 200 250 300 350 EXO Up Temperature (C) FIG. 14 Patent Application Publication Feb. 18, 2016 Sheet 15 of 35 US 2016/0045483 A1 lenalidomide/malonic acid cocrystal 5 O 4O 3 O desorption 2 O O O 20 40 60 80 100 Percent Relative Humidity FIG. 15 Patent Application Publication Feb. 18, 2016 Sheet 16 of 35 US 2016/0045483 A1 lenolidomide/molonic acid cocrystal 5.5- 5.0- 45 40 3.5- 91199||-!!!!!!!-- 3.0- 2.5- 2.0- 15 10 !===== 0.5- 0.0 3500 3000 2500 2000 1500 1000 500 Raman shift (cm-1) FIG. 16 Patent Application Publication Feb. 18, 2016 Sheet 17 of 35 US 2016/0045483 A1 cN do on N. cn or r n N - - r c Cn C on N d - C - no do N. r o or N d C C C N v Co do N. Cd N C N n c Cn oc C C Co od N. cn v. Cd Cod N N A C C CN c Cn Oce L. N. N. N. CN CN C C C. v- N. s. s. co co co co r r s s n an on on on an on on can on can on Siss SNNN \ | // --92 is is Sisar lenalidomidel/molonic acid COCrystal - N -e-2 - u-au-24 - 2-/Nils ty- e- addened r Cond nonr n w v- w we wor-ged we wr-y- 13 11 11 10 9 8 7 6 5 4 3 2 1 ppm Patent Application Publication Feb. 18, 2016 Sheet 18 of 35 US 2016/0045483 A1 lenalidomidel/molonic acid cocrystal 11 10 ppm FIG. 17B Patent Application Publication Feb. 18, 2016 Sheet 19 Of 35 US 2016/0045483 A1 SS SS &S & 888 :8 SS : S 8 8 SS S& &S : 8 & 8 3. & &š :8: 88:8: & /molonic acid cocrystal Patent Application Publication Feb. 18, 2016 Sheet 20 of 35 US 2016/0045483 A1 5e--004 2e--004 1e--004 Oe--000 2-Theta (deg) FIG. 19A lenalidomide/L-tartaric acid cocrystal 5 10 15 20 25 30 35 40 Degrees Two Theta FIG. 19B Patent Application Publication Feb. 18, 2016 Sheet 21 of 35 US 2016/0045483 A1 0.5 DSC20082 110 11.85% start-2000 TC2.0137 -100 0.0 N (0.5568mg) 90 80 g-5 70 Ne 60S a -1.0 E LL- 50.5 a- S E-15 40 30 -20 20 148.29C 10 -25 O 50 100 150 200 250 300 35 Exo Up Temperature (C) FIG. 20 Patent Application Publication Feb. 18, 2016 Sheet 22 of 35 US 2016/0045483 A1 lenalidomide/L-tartaric acid cocrystal 2 5 2 O 1 5 10 desorption 5 absorption O 20 40 60 80 100 Percent Relative Humidity FIG. 21 Patent Application Publication Feb. 18, 2016 Sheet 23 of 35 US 2016/0045483 A1 8 en N en N en - to No Lo N. c. oo No N- - - to No en O N en - c to cond or ob is ced as or c s - d do do or d is ad is no dry d oc - od at as od on s- ad is . o. oO N N C C CN CN C N o os oo to L. N. N. CN C C C. - N is s. cae cad ad go r r r s r. No ind a on CN can can can can on on can ea lenalidomidel/L-tortoric acid cocrystal 's- -- % - --- d - C L l N Nado v- son conce cans v- N Non N v- corr an on can s 13 12 11 10 9 8 7 6 5 4. 3 2 1 ppm Patent Application Publication Feb. 18, 2016 Sheet 24 of 35 US 2016/0045483 A1 ric dicid cocrystol FIG. 23 Patent Application Publication Feb. 18, 2016 Sheet 25 of 35 US 2016/0045483 A1 2.0e--004 1.5e+004 2-Theta (deg) FIG. 24 Patent Application Publication Feb. 18, 2016 Sheet 26 of 35 US 2016/0045483 A1 6,0e--005 g e 4.0e+003 2.0e--003 0.0e--000 2-Theta (deg) FIG. 25 Patent Application Publication Feb. 18, 2016 Sheet 27 of 35 US 2016/0045483 A1 5.0e--003 0.0e--000 10 20 30 40 2-Theta (deg) FIG. 26 Patent Application Publication Feb. 18, 2016 Sheet 28 of 35 US 2016/0045483 A1 gallic acid 5 O 15 20 25 30 35 40 Degrees Two-Theta FIG. 27 Patent Application Publication Feb. 18, 2016 Sheet 29 of 35 US 2016/0045483 A1 enolidomide form D 5 10 15 20 25 30 35 40 Degrees Two-Theta FIG. 28 Patent Application Publication Feb. 18, 2016 Sheet 30 of 35 US 2016/0045483 A1 engidomide form D 5 10 15 20 25 30 35 40 Degrees Two-Theta FIG. 29 Patent Application Publication Feb. 18, 2016 Sheet 31 of 35 US 2016/0045483 A1 enolidomide form A glycolic acid 5 10 15 20 25 30 35 40 Degrees Two-Theta FIG. 30 Patent Application Publication Feb. 18, 2016 Sheet 32 of 35 US 2016/0045483 A1 enolidomide form A 5 O 15 20 25 30 35 40 Degrees Two-Theta FIG.
Load more

Recommended publications
  • Suspect and Target Screening of Natural Toxins in the Ter River Catchment Area in NE Spain and Prioritisation by Their Toxicity
    toxins Article Suspect and Target Screening of Natural Toxins in the Ter River Catchment Area in NE Spain and Prioritisation by Their Toxicity Massimo Picardo 1 , Oscar Núñez 2,3 and Marinella Farré 1,* 1 Department of Environmental Chemistry, IDAEA-CSIC, 08034 Barcelona, Spain; [email protected] 2 Department of Chemical Engineering and Analytical Chemistry, University of Barcelona, 08034 Barcelona, Spain; [email protected] 3 Serra Húnter Professor, Generalitat de Catalunya, 08034 Barcelona, Spain * Correspondence: [email protected] Received: 5 October 2020; Accepted: 26 November 2020; Published: 28 November 2020 Abstract: This study presents the application of a suspect screening approach to screen a wide range of natural toxins, including mycotoxins, bacterial toxins, and plant toxins, in surface waters. The method is based on a generic solid-phase extraction procedure, using three sorbent phases in two cartridges that are connected in series, hence covering a wide range of polarities, followed by liquid chromatography coupled to high-resolution mass spectrometry. The acquisition was performed in the full-scan and data-dependent modes while working under positive and negative ionisation conditions. This method was applied in order to assess the natural toxins in the Ter River water reservoirs, which are used to produce drinking water for Barcelona city (Spain). The study was carried out during a period of seven months, covering the expected prior, during, and post-peak blooming periods of the natural toxins. Fifty-three (53) compounds were tentatively identified, and nine of these were confirmed and quantified. Phytotoxins were identified as the most frequent group of natural toxins in the water, particularly the alkaloids group.
    [Show full text]
  • Protein Phosphatases 1 and 2A and Their Naturally Occurring Inhibitors: Current Topics in Smooth Muscle Physiology and Chemical Biology
    J Physiol Sci (2018) 68:1–17 https://doi.org/10.1007/s12576-017-0556-6 REVIEW Protein phosphatases 1 and 2A and their naturally occurring inhibitors: current topics in smooth muscle physiology and chemical biology 1 2 3 1 Akira Takai • Masumi Eto • Katsuya Hirano • Kosuke Takeya • 4 5 Toshiyuki Wakimoto • Masaru Watanabe Received: 6 January 2017 / Accepted: 27 June 2017 / Published online: 5 July 2017 Ó The Author(s) 2017. This article is an open access publication Abstract Protein phosphatases 1 and 2A (PP1 and PP2A) Keywords Protein phosphorylation Á Protein phosphatase are the most ubiquitous and abundant serine/threonine 1 Á Protein phosphatase 2A Á Smooth muscle Á Phosphatase phosphatases in eukaryotic cells. They play fundamental inhibitors Á Signal transduction roles in the regulation of various cellular functions. This review focuses on recent advances in the functional studies of these enzymes in the field of smooth muscle physiology. Introduction Many naturally occurring protein phosphatase inhibitors with different relative PP1/PP2A affinities have been dis- Protein phosphatases 1 (PP1) and 2A (PP2A) are two of the covered and are widely used as powerful research tools. principal catalytic subunits that dephosphorylate proteins on Current topics in the chemical biology of PP1/PP2A inhi- serine and threonine residues in the cytosol of eukaryotic bitors are introduced and discussed, highlighting the cells. They are encoded by genes belonging to the PPP identification of the gene cluster responsible for the family and are abundantly expressed in all cell types. These biosynthesis of calyculin A in a symbiont microorganism enzymes achieve the substrate specificity and activity reg- of a marine sponge.
    [Show full text]
  • The Biosynthesis Pathway of Swainsonine, a New Anticancer
    J. Microbiol. Biotechnol. (2017), 27(11), 1897–1906 https://doi.org/10.4014/jmb.1709.09003 Research Article Review jmb The Biosynthesis Pathway of Swainsonine, a New Anticancer Drug from Three Endophytic Fungi Zhenhui Ren, Runjie Song, Shuai Wang, Haiyun Quan, Lin Yang, Lu Sun, Baoyu Zhao, and Hao Lu* College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi 712100, P.R. China Received: September 1, 2017 Revised: October 9, 2017 Swainsonine (SW) is the principal toxic ingredient of locoweed plants that causes locoism Accepted: October 12, 2017 characterized by a disorder of the nervous system. It has also received widespread attention in First published online the medical field for its beneficial anticancer and antitumor activities. Endophytic fungi, November 3, 2017 Alternaria sect. Undifilum oxytropis isolated from locoweeds, the plant pathogen Slafractonia *Corresponding author leguminicola, and the insect pathogen Metarhizium anisopliae, produce swainsonine. Acquired Phone: +86-29-87092429; SW by biofermentation has a certain foreground and research value. This paper mainly Fax: +86-29-87091032; E-mail: [email protected] summarizes the local and foreign literature published thus far on the swainsonine biosynthesis pathway, and speculates on the possible regulatory enzymes involved in the synthesis pathway within these three fungi in order to provide a new reference for research on swainsonine biosynthesis by endophytic fungi. pISSN 1017-7825, eISSN 1738-8872 Copyright© 2017 by Keywords: Swainsonine, biosynthesis, Alternaria oxytropis, Slafractonia leguminicola, Metarhizium The Korean Society for Microbiology anisopliae and Biotechnology Introduction leukemia [11] and showed that all patients received a good therapeutic effect. SW is a specific inhibitor of α-mannosidase Swainsonine (SW) is an indolizidine alkaloid that was II in the golgi complex, which can affect the synthesis of first identified from Swainsona canescens, a toxic legume various carbolydrates, glycoproteins, and glycolipids, that is found in Australia [1].
    [Show full text]
  • Isolation and Identification of Cyclic Polyketides From
    ISOLATION AND IDENTIFICATION OF CYCLIC POLYKETIDES FROM ENDIANDRA KINGIANA GAMBLE (LAURACEAE), AS BCL-XL/BAK AND MCL-1/BID DUAL INHIBITORS, AND APPROACHES TOWARD THE SYNTHESIS OF KINGIANINS Mohamad Nurul Azmi Mohamad Taib, Yvan Six, Marc Litaudon, Khalijah Awang To cite this version: Mohamad Nurul Azmi Mohamad Taib, Yvan Six, Marc Litaudon, Khalijah Awang. ISOLATION AND IDENTIFICATION OF CYCLIC POLYKETIDES FROM ENDIANDRA KINGIANA GAMBLE (LAURACEAE), AS BCL-XL/BAK AND MCL-1/BID DUAL INHIBITORS, AND APPROACHES TOWARD THE SYNTHESIS OF KINGIANINS . Chemical Sciences. Ecole Doctorale Polytechnique; Laboratoires de Synthase Organique (LSO), 2015. English. tel-01260359 HAL Id: tel-01260359 https://pastel.archives-ouvertes.fr/tel-01260359 Submitted on 22 Jan 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ISOLATION AND IDENTIFICATION OF CYCLIC POLYKETIDES FROM ENDIANDRA KINGIANA GAMBLE (LAURACEAE), AS BCL-XL/BAK AND MCL-1/BID DUAL INHIBITORS, AND APPROACHES TOWARD THE SYNTHESIS OF KINGIANINS MOHAMAD NURUL AZMI BIN MOHAMAD TAIB FACULTY OF SCIENCE UNIVERSITY
    [Show full text]
  • WO 2014/160698 Al 2 October 2014 (02.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/160698 Al 2 October 2014 (02.10.2014) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07H 19/12 (2006.01) A61P 35/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/706 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, PCT/US20 14/03 1705 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 25 March 2014 (25.03.2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/805,459 26 March 2013 (26.03.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: CELGENE CORPORATION [US/US]; 86 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Morris Avenue, Summit, NJ 07901 (US).
    [Show full text]
  • Chemical Compound Outline (Part II)
    Chemical Compound Outline (Part II) Ads by Google Lil Wayne Lyrics Search Lyrics Song Wayne Dalton Wayne's Word Index Noteworthy Plants Trivia Lemnaceae Biology 101 Botany Search Major Types Of Chemical Compounds In Plants & Animals Part II. Phenolic Compounds, Glycosides & Alkaloids Note: When the methyl group containing Jack's head is replaced by an isopropyl group, the model depicts a molecule of menthol. Back To Part I Find On This Page: Type Word Inside Box; Find Again: Scroll Up, Click In Box & Enter [Try Control-F or EDIT + FIND at top of page] **Note: This Search Box May Not Work With All Web Browsers** Go Back To Chemical VI. Phenolic Compounds Compounds Part I: VII. Glycosides Table Of Contents VIII. Alkaloids Search For Specific Compounds: Press CTRL-F Keys If you have difficulty printing out this page, try the PDF version: Click PDF Icon To Read Page In Acrobat Reader. See Text In Arial Font Like In A Book. View Page Off-Line: Right Click On PDF Icon To Save Target File To Your Computer. Click Here To Download Latest Acrobat Reader. Follow The Instructions For Your Computer. Types Of Phenolic Compounds: Make A Selection VI. Phenolic Compounds: Composed of one or more aromatic benzene rings with one or more hydroxyl groups (C-OH). This enormous class includes numerous plant compounds that are chemically distinct from terpenes. Although the essential oils are often classified as terpenes, many of these volatile chemicals are actually phenolic compounds, such as eucalyptol from (Eucalytus globulus), citronellal from (E. citriodora) and clove oil from Syzygium aromaticum.
    [Show full text]
  • ACVPM Toxicology Review
    Top 20 Toxicology Review “I always keep a supply of stimulant handy in case I see a snake………..which I also keep handy. “ - WC Fields The Top 10 (in no particular order….) 1. Bracken fern Pteridium aquilinum –THINK bloody urine cows, ataxic horse 2. Copper –THINK hemolytic crisis, port wine urine, gunmetal kidneys 3. Cyanide—THINK Bright red blood, like bright red cherries 4. Anticoagulant rodenticides--–THINK hemolytic crisis 5. Ethylene glycol (antifreeze) –THINK kidney failure 6. Insecticides (esp. OPPs, carbamates) –THINK miosis, drool, vomiting, diarrhea, seizure 7. Lead--–THINK GI signs + Neuro Sx (blindness) 8. NITRATE / NITRITE Toxicity –THINK Dark Chocolate blood 9. Mycotoxins Aflatoxins –THINK hepatotoxic, carcinogenic Zearalonone / moldy corn –THINK estrogenism, repro dysfunction 10. Nonprotein nitrogen (NPN) ‘Ammonia tox‘ (urea, ammonia, etc) –THINK Bov Bonkers 1 www.zukureview.com © Zuku LLC, All Rights Reserved I. Pathognomonics, weird names, weird smells, NOEL 1. Gunmetal grey kidneys-Cu tox Trifolium subterraneum, cz mineral imbal Senecio, Heliotropum damage liver cz Cu tetention 2. Port wine urine-Cu tox see above 3. Cherry-red blood-Cyanide pitted fruits 4. Chocolate-brown blood- Nitrates 5. “SPECTACLES” Depigmentation around eyes- molybdenul tox 6. Smells a. Garlicky breath- selenium tox b. Bitter almonds in rumen-cyanide c. “Mouse-like odor” to crushed leaves- Conium maculatum (poison hemlock) 7. Diseases a. “Alkali disease”- selenium toxicity (Astragalus, Oxytropis) b. “Blind staggers”-selenium tox c. “Cracker heels” clicking dewclaws w/ Astragalus-miserotoxin d. “Milk sickness” in early American settlers- Eupatorium (white snakeroot) e. “Crooked calf” syndrome- torticollis, carpal flexure, scoliosis in calves exposed in utero d. 40-70 to Lupinus (Lupine, bluebonnet) f.
    [Show full text]
  • Mortison 1.Pdf
    Chemical and Biochemical Interrogation of Molecular Specificity in Modular Polyketide Synthases by Jonathan D. Mortison A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Chemistry) in the University of Michigan 2010 Doctoral Committee: Professor David H. Sherman, Chair Professor John Montgomery Associate Professor Anna K. Mapp Assistant Professor Jason E. Gestwicki Acknowledgements I would like to thank my advisor, Dr. David H. Sherman, for the opportunity to join his research group at the University of Michigan. It has been a tremendously rewarding experience to work with him and explore many exciting projects at the interface of chemistry and biology. During my graduate career, his enthusiasm for science and perpetual optimism created an exceptionally positive atmosphere for learning. I am also grateful to have accompanied David on dive expeditions to gather samples for our natural products collection. These trips to Papua New Guinea (2007) and Costa Rica (2009) were wonderful opportunities both culturally and scientifically, allowing me to gain a unique view of these rich and biodiverse marine environments. I express thanks to my committee members, Dr. John Montgomery, Dr. Anna Mapp and Dr. Jason Gestwicki for serving on my thesis committee and providing helpful conversations during the course of my graduate work. I would also like to acknowledge co-workers and collaborators, especially Dr. Jeff Kittendorf and Dr. Sathish Rajamani for their work and guidance during the molecular cloning and biochemistry portion of my doctoral studies. Additional thanks go to graduate student Chris Rath for useful discussions on mass spectrometry and ongoing collaborations with FT-ICR MS studies.
    [Show full text]
  • Regulation of Cardiac PKA Signaling by Camp and Oxidants
    antioxidants Review Regulation of Cardiac PKA Signaling by cAMP and Oxidants Friederike Cuello 1,2,* , Friedrich W. Herberg 3,* , Konstantina Stathopoulou 1,2 , Philipp Henning 3 and Simon Diering 1,2 1 Institute of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; [email protected] (K.S.); [email protected] (S.D.) 2 DZHK (German Center for Cardiovascular Research), Partner site Hamburg/Kiel/Lübeck, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany 3 Department of Biochemistry, University Kassel, Heinrich-Plett-Str. 40, 34132 Kassel, Germany; [email protected] * Correspondence: [email protected] (F.C.); [email protected] (F.W.H.); Tel.: +49-(0)-40/7410-57204 (F.C.); +49-(0)-561/804-4511 (F.W.H.); Fax: +49-(0)-40/7410-54876 (F.C.); +49-(0)-561/804-4466 (F.W.H.) Abstract: Pathologies, such as cancer, inflammatory and cardiac diseases are commonly associated with long-term increased production and release of reactive oxygen species referred to as oxidative stress. Thereby, protein oxidation conveys protein dysfunction and contributes to disease progression. Importantly, trials to scavenge oxidants by systemic antioxidant therapy failed. This observation supports the notion that oxidants are indispensable physiological signaling molecules that induce oxidative post-translational modifications in target proteins. In cardiac myocytes, the main driver of cardiac contractility is the activation of the β-adrenoceptor-signaling cascade leading to increased cel- lular cAMP production and activation of its main effector, the cAMP-dependent protein kinase (PKA). PKA-mediated phosphorylation of substrate proteins that are involved in excitation-contraction Citation: Cuello, F.; Herberg, F.W.; coupling are responsible for the observed positive inotropic and lusitropic effects.
    [Show full text]
  • Fostriecin-Mediated G2-M-Phase Growth Arrest Correlates With
    [CANCER RESEARCH 58. 3611-3619, August 15, 1998] Fostriecin-mediated G2-M-phase Growth Arrest Correlates with Abnormal Centrosome Replication, the Formation of Aberrant Mitotic Spindles, and the Inhibition of Serine/Threonine Protein Phosphatase Activity1 Aiyang Cheng, Ron Balczon, Zhuang Zuo, Jamie S. Koons, AiméeH. Walsh, and Richard E. Honkanen2 Departments of Biochemistry and Molecular Biology ¡A.C, Z Z. J. S. K., A. H. W.. R. E. H.I ami Structural and Cellular Biology ¡R.B.¡,College of Medicine. University of South Alabama. Mobile. Alabama 36688 ABSTRACT protein synthesis (7). Although these studies demonstrated that fos triecin affects a process essential for replication and transcription, no Fostriecin, a structurally unique phosphate ester, is presently under direct effect on DNA polymerase, RNA polymerase, or enzymes evaluation in clinical trials to determine its potential use as an antitumor within the purine or pyrimidine biosynthetic pathways has been noted drug in humans. Fostriecin has been reported as having inhibitory activity against DNA topoisomerase type II and protein phosphatases implicated (3, 7). Fostriecin was then shown to block cell growth in the G2 phase in cell-cycle control. However, the relative contribution of these mecha of the cell cycle and to have inhibitory activity against type II DNA nisms to the antitumor activity of Iosi ricchi has not yet been elucidated. In topoisomerase from Ehrlich ascites carcinomas (8), with 100 /J.M this study, after confirming that fostriecin is a potent inhibitor of
    [Show full text]
  • Principles and Methods for the Assessment of Neurotoxicity Associated with Exposure to Chemicals
    lnkr national Environmental Health Criteria 60 Principles and Methods for the Assessment of Neurotoxicity Associated With Exposure to Chemicals Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization WORLD HEALTH ORGANIZATION GENEVA 1986 Other titles available in the ENVIRONMENTAL HEALTH CRITERIA series include: 1. Mercury 32. Methylene Chloride 2. Polychlorinated Biphenyls and 33. Epichlorohydrin Terphenyls 34. Chlordane 3. Lead 35. Extremely Low Frequency 4. Oxides of Nitrogen (ELF) Fields 5. Nitrates, Nitrites, and 36. Fluorides and Fluorine N-Nitroso Compounds 37. Aquatic (Marine and 6. Principles and Methods for Freshwater) Biotoxins Evaluating the Toxicity of 38. Heptachlor Chemicals, Part 1 39. Paraquat and Diquat 7. Photochemical Oxidants 40. Endosulfan 8. Sulfur Oxides and Suspended 41. Quintozene Particulate Matter 42. Tecnazene 9. DDT and its Derivatives 43. Chlordecone 10. Carbon Disulfide 44. Mirex 11. Mycotoxins 45. Camphechlor 12. Noise 46. Guidelines for the Study of 13. Carbon Monoxide Genetic Effects in Human 14. Ultraviolet Radiation Populations 15. Tin and Organotin Compounds 47. Summary Report on the 16. Radiofrequency and Microwaves Evaluation of Short-Term Tests 17. Manganese for Carcinogens (Collaborative 18. Arsenic Study on In Vitro Tests) 19. Hydrogen Sulfide 48. Dimethyl Sulfate 20. Selected Petroleum Products 49. Acrylamide 21. Chlorine and Hydrogen 50. Trichloroethylene Chloride 51. Guide to Short-Term Tests for 22. Ultrasound Detecting Mutagenic and 23. Lasers and Optical Radiation Carcinogenic Chemicals 24. Titanium 52. Toluene 25. Selected Radionuclides 53. Asbestos and Other Natural 26. Styrene Mineral Fibres 27. Guidelines on Studies in 54. Ammonia Environmental Epidemiology 55.
    [Show full text]
  • Blackpatch of Clover, Cause of Slobbers Syndrome: a Review of the Disease and the Pathogen, Rhizoctonia Leguminicola
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector REVIEW published: 27 January 2016 doi: 10.3389/fvets.2016.00003 Blackpatch of Clover, Cause of Slobbers Syndrome: A Review of the Disease and the Pathogen, Rhizoctonia leguminicola Isabelle A. Kagan* Forage-Animal Production Research Unit, USDA Agricultural Research Service, Lexington, KY, USA Rhizoctonia leguminicola Gough and Elliott is a widely used name for the causal agent of blackpatch disease of red clover (Trifolium pratense L.). This fungal pathogen produces alkaloids (slaframine and swainsonine) that affect grazing mammals. Slaframine causes livestock to salivate profusely, and swainsonine causes neurological problems. Although the blackpatch fungus was classified as aRhizoctonia species (phylum Basidiomycota), morphological studies have indicated that it is in the phylum Ascomycota, and sequenc- ing data have indicated that it may be a new genus of ascomycete. The effects of the alkaloids on grazing mammals and their biosynthetic pathways have been extensively studied. In contrast, few studies have been done on management of the disease, which Edited by: requires a greater understanding of the pathogen. Methods of disease management Arthur Louis Goetsch, have included seed treatments and fungicides, but these have not been investigated Langston University, USA Reviewed by: since the 1950s. Searches for resistant cultivars have been limited. This review summa- Daniel Cook, rizes the biological effects and biosynthetic precursors of slaframine and swainsonine. USDA Agricultural Research Service, Emphasis is placed on current knowledge about the epidemiology of blackpatch disease USA Rebecca Creamer, and the ecology and taxonomy of the pathogen.
    [Show full text]